Bovie Medical Corporation to Release Second Quarter of Fiscal Year 2018 Financial Results on August 1, 2018
23 Juillet 2018 - 10:05PM
Business Wire
Bovie Medical (NYSE: BVX), a maker of medical devices and
supplies and the developer of J-Plasma®, a patented surgical
product marketed and sold under the Renuvion™ Cosmetic Technology
brand in the cosmetic surgery market, today announced that
financial results for the second quarter of fiscal year 2018 will
be released after the market closes on Wednesday, August 1.
About Bovie Medical Corporation
Bovie Medical Corporation is a leading maker of medical devices
and supplies as well as the developer of J-Plasma® (marketed and
sold under the Renuvion™ Cosmetic Technology brand in the cosmetic
surgery market), a patented plasma-based surgical product for
cutting, coagulation and ablation of soft tissue. J-Plasma/Renuvion
technology utilizes a helium ionization process to produce a
stable, focused beam of plasma that provides surgeons with greater
precision, and minimal invasiveness. The new J-Plasma/Renuvion
handpieces with Cool-Coag™ technology deliver the precision of
helium plasma energy, the power of traditional monopolar
coagulation and the efficiency of plasma beam coagulation -
enabling thin-layer ablation and dissection and fast coagulation
with a single instrument, minimizing instrument exchange and
allowing a surgeon to focus on their patient and their procedures.
With Cool-Coag technology, the new J-Plasma/Renuvion handpieces can
deliver three distinctly different energy modalities - further
increasing the utility and versatility of the system. Bovie Medical
Corporation is also a leader in the manufacture of a range of
electrosurgical products and technologies, marketed through both
private labels and the Company’s own well-respected brands (Bovie®,
IDS™ and DERM™) to distributors worldwide. The Company also
leverages its expertise through original equipment manufacturing
(OEM) agreements with other medical device manufacturers. For
further information about the Company and its products, please
refer to the Bovie Medical Corporation website at
www.boviemedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180723005557/en/
Investor Relations:Westwicke Partners on behalf of Bovie
Medical CorporationMike Piccinino, CFAManaging
Director443-213-0500investor.relations@boviemed.com
Bovie (AMEX:BVX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bovie (AMEX:BVX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Bovie Medical Corp. (American Stock Exchange): 0 recent articles
Plus d'articles sur Bovie Medical Corp.